Glasdegib Dimaleate: Synthesis, Characterization and Comparison of Its Properties with Monomaleate Analogue

Boris Peklar 1,2, Franc Perdih 3, Damjan Makuc 4,5, Janez Plavec 4,5, Jérôme Cluzeau 1, Zoran Kitanovski 1,6,* and Zdenko Ćasar 1,6,7,*

1 Lek Pharmaceuticals d.d., Sandoz Development Center Slovenia, Kolodvorska 27, 1234 Menges, Slovenia
2 Faculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova ulica 17, 2000 Maribor, Slovenia
3 Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, 1000 Ljubljana, Slovenia
4 Slovenian NMR Centre, National Institute of Chemistry, Hajdrihova 19, 1000 Ljubljana, Slovenia
5 EN-FIST Centre of Excellence, Trg Osvobodilne Fronte 13, 1000 Ljubljana, Slovenia
6 Faculty of Pharmacy, University of Ljubljana, Askerčeva Cesta 7, 1000 Ljubljana, Slovenia
* Correspondence: zdenko.casar@sandoz.com or zdenko.casar@ffa.uni-lj.si; Tel.: +386-1-5802079

Abstract: Glasdegib is a recently approved drug for the treatment of acute myeloid leukemia. It is formulated and marketed in monomaleate salt form. In our investigation, we were able to prepare a glasdegib dimaleate form, which could, in theory, exist in double-salt form or as a mixture of salt and co-crystal species. Therefore, the obtained crystals of glasdegib dimaleate were characterized via 15N ssNMR and single-crystal X-ray diffraction, which revealed that the obtained glasdegib dimaleate exists in double-salt form. This is a surprising finding based on the pKa values for glasdegib and maleic acid. Furthermore, we fully characterized the new dimaleate form using thermal analyses (DSC and TGA) and spectroscopy (IR and Raman). Finally, the physicochemical properties, such as solubility and chemical stability, of both forms were determined and compared.

Keywords: glasdegib; salts; X-ray diffraction; ssNMR; stability; solubility

1. Introduction

Acute myeloid leukemia (AML) is a cancer disease that affects the blood and bone marrow. It represents a type of acute leukemia that is most commonly found in adults and can progress rapidly without proper treatment [1]. In recent years, several new therapies for the treatment of AML have appeared. These therapies involve kinase inhibitors (FLT3 inhibitors), IDH1/IDH2 inhibitors, BCL-2 inhibitors, hedgehog inhibitors and others [2–15]. Glasdegib (Figure 1), 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea (previously also known as PF-04449913), was developed by Pfizer for the treatment of AML [16–19]. Glasdegib inhibits the hedgehog signaling pathway, known to be associated with a broad range of cancers, via the binding to and inhibition of transmembrane protein Smoothened [17,19–23]. It was approved in November 2018 by the U.S. Food and Drug Administration and in June 2020 by the European Medicines Agency for use, in combination with low-dose cytarabine, as a treatment for newly diagnosed AML in patients aged ≥75 and/or unfit for intensive induction chemotherapy [20–23]. Glasdegib was developed as a film-coated tablet for oral use which contains the active pharmaceutical ingredient in the form of a monomaleate salt (Figure 1) [24]. Glasdegib was reported to have pKa values of 1.7 (benzimidazole nitrogen) and 6.1 (methylpiperidine nitrogen) [24,25], which makes it suitable for the formation of mono-salts with carboxylic acids. Although several salts of glasdegib have been reported in the literature (e.g., maleate, (S)-mandelate and dihydrochloride, which forms a hydrate) [17,26], the monomaleate salt has the most favorable properties in terms of chemical stability, thereby forming the lowest...
levels of (2S,4R)-epimer under stress conditions (50 °C and 75% relative humidity over 6 weeks) [26]. Furthermore, glasdegib monomaleate is a moderately soluble drug [27] with an aqueous solubility of 1.7 mg/mL [24,25]. Therefore, there is a need for the development of alternative glasdegib salts with better stability and/or solubility.

In our study we were able to isolate a glasdegib dimaleate form upon treatment of glasdegib monomaleate with an additional amount of maleic acid [28]. Based on the pKₐ values of glasdegib [24,25] and maleic acid (pKₐ₁ = 1.9 and pKₐ₂ = 6.3) [29], the structure of this novel form with regard to the ionization state was not evident. Thus, in this report, we provide full details on the preparation and characterization of the glasdegib dimaleate form. Interestingly, glasdegib dimaleate proved to be a double-salt form, which is surprising. Furthermore, we compare its properties with its monomaleate analogue.

![Chemical structures](image)

**Figure 1.** Chemical structure of glasdegib, maleic acid, glasdegib monomaleate and glasdegib dimaleate and their reported pKₐ values [24,25,29].

### 2. Materials and Methods

#### 2.1. Materials

For the purpose of this study, glasdegib monomaleate (Taros, Dortmund, Germany) was used.

For the purpose of glasdegib dimaleate synthesis, maleic acid, sodium hydroxide, methanol, ethyl acetate and dichloromethane were purchased from Merck KGaA (Darmstadt, Germany). Hydrochloric acid and isopropanol were obtained from FluoroChem (Derbyshire, UK).
2.2. Characterization Methods

2.2.1. Fourier Transform Infrared (FTIR) Measurements

FTIR spectra were collected using a Nicolet™ iS50 FTIR Spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) with a KBr disk.

2.2.2. Raman Measurements

Raman spectra were collected using a Nicolet™ iS50 FTIR Spectrometer (Thermo Fisher Scientific Inc., Waltham, MA, USA) with an iS50 Raman Module.

2.2.3. Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis (TGA) Measurements

DSC thermograms were acquired using a differential scanning calorimeter DSC 3+ STAR® System instrument (Mettler Toledo, Columbus, OH, USA), and TGA thermograms were collected using a TGA/DSC 1 STAR® System instrument (Mettler Toledo, Polaris Parkway, Columbus, OH, USA). The sample was heated in a 40 microliter aluminum pan with a pierced aluminum lid from 30 to 300 °C at a rate of 10 K/min. Nitrogen (purge rate 200 mL/min) was used as a purge gas.

2.2.4. Powder X-ray Diffraction (PXRD) Measurements

Bulk powder samples of glasdegib base, dihydrochloride, monomaleate and dimaleate were analyzed via powder X-ray diffraction using the PANalytical Empyrean diffractometer (Malvern Panalytical GmbH, Kassel, Germany) equipped with a theta/theta coupled goniometer in transmission geometry, Cu-Kα1, 2 radiation (wavelength 0.15419 nm) with a focusing mirror and a solid state PIXcel1D detector. The patterns (Figures S16, S18 and S20–S23) were recorded at a tube voltage of 45 kV and a tube current of 40 mA, applying a step size of 0.026° 2-Theta with 50 s per step in the angular range of 2° to 40° 2-Theta under ambient conditions. Automatic divergence and antiscatter slits were used to irradiate 10 mm of sample length.

2.2.5. Nuclear Magnetic Resonance (NMR) Spectroscopy

All solutions’ NMR spectra (Figures S27–S30) were recorded at 298 K using a Bruker Avance III 500 MHz spectrometer (Bruker BioSpin, Rheinstetten, Germany). The spectrometer was equipped with a 5 mm BBO, Z-gradient probe operating at a 1H resonance frequency of 500 MHz and a 13C resonance frequency of 125 MHz. Spectra were acquired and processed using Bruker TopSpin software, version 3.1. 1H NMR chemical shifts (δH) and 13C NMR chemical shifts (δC) are quoted in parts-per-million (ppm) downfield from tetramethylsilane (TMS), and coupling constants (J) are quoted in Hertz (Hz). The abbreviations for NMR data are s (singlet), d (doublet), t (triplet), sept (septet) and m (multiplet).

2.2.6. Solid-State Nuclear Magnetic Resonance (ssNMR) Analysis

ssNMR spectra were acquired using the Agilent Technologies NMR System 600 MHz NMR spectrometer (Varian Inc., Palo Alto, CA, USA) equipped with a 3.2 mm NB dual resonance HX MAS probe. The Larmor frequencies of proton and nitrogen nuclei were 599.39 and 60.75 MHz, respectively. 1H NMR chemical shifts are reported relative to external reference adamantane (δH 1.85 ppm), which corresponds to the TMS signal at δH 0.0 ppm. 15N NMR chemical shifts are reported relative to ammonium sulfate (δN −355.7 ppm), which corresponds to the nitromethane signal at δN 0.0 ppm. Samples were spun at 20,000 (1H) and 10,000 Hz (15N). A short excitation time of 200 µs was used to transfer polarization, relaxation delays of 1.5–4.75 s and at least 50,000 repetitions.

2.2.7. X-ray Single-Crystal Analysis

Single-crystal X-ray diffraction data for glasdegib monomaleate and glasdegib dimaleate were collected on an Agilent Technologies SuperNova Dual diffractometer (Yarnston, UK) using an Atlas detector with monochromated Cu-Kα radiation (λ = 1.54184 Å) at
150 K. The data were processed using CrysAlis Pro [30]. Structures were solved via the SHELXT program [31] and refined using a full-matrix least-squares procedure based on \( F^2 \) with SHELXL [32] using the Olex2 program suite [33]. All non-hydrogen atoms were refined anisotropically. All hydrogen atoms were readily located in difference Fourier maps. Hydrogen atoms bonded to carbon atoms were subsequently treated as riding atoms in geometrically idealized positions with \( U_{iso}(H) = kU_{eq}(C) \), where \( k = 1.5 \) for methyl groups—which were permitted to rotate but not to tilt—and 1.2 for all other H atoms. N–H groups were refined by restraining bonding distances, except for H atoms attached to N4 with \( U_{iso}(H) = 1.2U_{eq}(N) \). Hydrogen atoms involved in the intramolecular O–H···O interactions in maleate monoanions were refined freely with \( U_{iso}(H) = 1.5U_{eq}(O) \). Geometric parameters were calculated using the SHELXL [32] and Platon programs [34]. The crystallographic data are listed in Table 1.

Table 1. Crystallographic data for glasdegib monomaleate and glasdegib dimaleate.

|                          | Glasdegib Monomaleate | Glasdegib Dimaleate |
|--------------------------|-----------------------|---------------------|
| CCDC number              | 2,180,664             | 2,180,665           |
| Formula                  | C_{25}H_{26}N_{6}O_{5} | C_{29}H_{30}N_{6}O_{9} |
| \( M_r \)                | 490.52                | 606.59              |
| \( T (K) \)              | 150.00(10)            | 150.00(10)          |
| Crystal system           | monoclinic            | orthorhombic        |
| Space group              | \( P2_1 \)            | \( P2_1\)\(_2\)\(_2\) \(_1\) |
| \( a \) (Å)              | 9.7312(3)             | 10.3645(2)         |
| \( b \) (Å)              | 12.3780(3)            | 14.5078(3)         |
| \( c \) (Å)              | 10.5764(3)            | 19.2377(3)         |
| \( \alpha \) (°)         | 90                    | 90                  |
| \( \beta \) (°)          | 113.776(3)            | 90                  |
| \( \gamma \) (°)         | 90                    | 90                  |
| Volume (Å\(^3\))        | 1165.83(6)            | 2892.71(10)        |
| \( Z \)                  | 2                     | 4                   |
| \( D_c \) (g/cm\(^3\))  | 1.397                 | 1.393               |
| \( \mu \) (mm\(^{-1}\)) | 0.827                 | 0.885               |
| \( F(000) \)             | 516.0                 | 1272.0              |
| Reflections collected    | 8533                  | 10926               |
| Independent reflections  | 4415 (0.0196)         | 5775 (0.0376)      |
| Data/restraints/parameters | 4415/3/342           | 5775/4/419         |
| \( R, wR \) \( \{I > 2\sigma(I)\} \) a | 0.0284, 0.0718 | 0.0436, 0.1047 |
| \( R, wR \) (all data) a | 0.0304, 0.0737 | 0.0499, 0.1104 |
| GOF, \( S \) b          | 1.039                 | 1.052               |
| Largest diff. peak/hole/e Å\(^{-3}\) | 0.15/−0.16 | 0.27/−0.21 |
| Flack parameter          | −0.10(8)              | 0.23(13)            |

\( a = \sum \left| F_A \right| - \left| F_c \right| / \sum \left| F_A \right|, \quad wR = \left[ \sum (w(F_o^2 - F_c^2)^2) / \sum w(F_o^2) \right]^{1/2}, \quad b = \left[ \sum (F_o^2 - F_c^2)^2 / (n/p) \right]^{1/2}, \quad \text{where} \quad n \text{ is the number of reflections and} \quad p \text{ is the total number of refined parameters.} \)

2.2.8. Ultra-High-Performance Liquid Chromatography (UHPLC) Method

The solubility of glasdegib and related substances/degradation products were measured using ultra-high-performance liquid chromatography (UHPLC) with UV detection. For that purpose, an Acquity UPLC system (Waters, Millford, MA, USA) equipped with a quaternary solvent manager (QSM), a sample manager (SM), a temperature-controlled column compartment and a tunable UV (TUV) detector was used. The method conditions were as follows: column: Acquity UPLC CSH C18 (1.7 µm, 100 mm × 2.1 mm); mobile phase A: A = ammonium bicarbonate (pH 9.0; 10 mM) pH-adjusted using ammonia solution (25%); mobile phase B: B = 100% ACN; pump flow: 0.4 mL/min; injection volume: 1 µL; column temperature: 30 °C; autosampler temperature: 10 °C; detection wavelength: 270 nm; needle-wash solvent: ACN-water (1:9, v/v); purge wash solvent: methanol-water (1:9, v/v); sample solvent composition: methanol-water (3:7, v/v); gradient: t = 0 min, 15% B; t = 0.5 min, 15% B; t = 11 min, 75% B; t = 13 min, 75% B; t = 13.5 min, 15% B; re-equilibration = 4.5 min; and \( t_R \) (glasdegib) = 9.0 min (Figure S24).
The concentrations of glasdegib salt for solubility measurements and for the determination of related substances/degradation products were 0.2 and 0.5 mg/mL, respectively.

2.2.9. Chiral High-Performance Liquid Chromatography (HPLC) Method

The chiral purity of glasdegib was determined using an Alliance 2695 Separations Module (Waters, Millford, MA, USA) equipped with a quaternary pump, an autosampler, temperature-controlled column compartment and a 2487 Dual Absorbance Detector (Waters, Millford, MA, USA). The method conditions were as follows: column: Chiralpak IC (5 µm, 250 mm × 4.6 mm; Daicel Corp, Tokyo, Japan); mobile phase A: A = 100% heptane; mobile phase B: B = 2-propanol containing 0.1% (v/v) diethylamine; pump flow: 1.5 mL/min; injection volume: 10 µL; column temperature: 25 °C; autosampler temperature: 5 °C; detection wavelength: 270 nm; needle-wash solvent: 100% 2-propanol; sample solvent: 100% methanol; gradient: t = 0 min, 10% B; t = 0.5 min, 10% B; t = 20.5 min, 40% B; t = 27 min, 60% B; t = 28 min, 10% B; re-equilibration = 12 min; tR (glasdegib) = 8.7 min; and tR (2S,4R-epimer) = 15.8 min (Figure S25). The concentration of glasdegib salt for the determination of chiral purity was 1.0 mg/mL.

2.2.10. Stress Stability Testing

Preliminary stress stability testing was conducted using dynamic vapor sorption apparatus (ProUmid SPSx-1µ Sorption Test System, Ulm, Germany). Samples of glasdegib monomaleate and glasdegib dimaleate were exposed to a temperature of 40 °C and relative humidity of 75% for 3 months. Samples were taken for analysis after 1, 2 and 3 months and analyzed via UHPLC (purity), chiral HPLC (chiral purity) and PXRD (form purity).

2.2.11. Dissolution and Solubility Testing

Dissolution and solubility were evaluated for both glasdegib monomaleate and glasdegib dimaleate. Dissolution was tested at different pH values using the following buffer solutions: pH 1.2 (United States Pharmacopeia 29), pH 4.0 (European Pharmacopoeia 7.0, ref. 4013800), pH 5.5 (European Pharmacopoeia 7.0, ref. 4002000) and pH 7.0 (European Pharmacopoeia 7.0, ref. 4008200) at 37 °C and 300 rpm using an EasyMax 102 reactor system (Mettler Toledo, Greifensee, Switzerland) using 50 mL reactor and a magnetic stirrer. Experiments were performed by adding excess glasdegib salts into the desired buffer solution already set at 37 °C. Samples were taken after stopping the stirring for 5–10 min (decantation) to avoid the contamination of samples with insoluble particles. Samples were then analyzed via UHPLC to measure glasdegib concentration.

2.3. Synthesis Methods and Characterization Data

To facilitate the ssNMR characterization of glasdegib dimaleate, standards of glasdegib base and glasdegib dihydrochloride were prepared from glasdegib maleate.

2.3.1. Characterization of Glasdegib Monomaleate

DSC (10 °K/min): 195.4 °C onset, 202.2 °C peak; FTIR (KBr): 3424, 3326, 3297, 3275, 3188, 3042, 2975, 2954, 2912, 2837, 2787, 2750, 2219, 1690, 1602, 1535, 1499, 1463, 1445, 1411, 1387, 1359, 1329, 1319, 1273, 1261, 1240, 1218, 1174, 1143, 1113, 1096, 1070, 1061, 1030, 1016, 1008, 986, 960, 927, 901, 861, 847, 829, 801, 771, 755, 716, 673, 570, 550, 520, 508, 495, 480, 454 and 420 cm⁻1; Raman: 3118, 3072, 3059, 3029, 3013 2988, 2976, 2955, 2933, 2219, 1691, 1613, 1589, 1535, 1490, 1445, 1432, 1387, 1329, 1320, 1288, 1273, 1261, 1233, 1208, 1175, 1145, 1113, 1070, 1035, 1023, 1014, 997, 966, 926, 911, 901, 874, 841, 830, 800, 782, 748, 729, 716, 676, 646, 620, 561, 551, 520, 511, 495, 480, 466, 455, 445, 422 and 401 cm⁻¹;1H NMR (MeOD, 500 MHz): δ 7.68–7.62 (m, 2H), 7.59 (s, 4H), 7.34–7.30 (m, 2H), 4.57 (s, 2H), 4.27–4.22 (m, 1H), 3.61 (d, J = 12.8 Hz, 1H), 3.30–3.23 (m, 1H), 2.67 (s, 3H), 2.48–2.36 (m, 2H), 2.25 (ddt, J = 15.1, 11.1, 4.2 Hz, 1H) and 2.08 (dt, J = 14.9, 4.5 Hz, 1H) ppm;13C NMR (MeOD, 125 MHz, proton-decoupled): δ 170.80, 156.73, 150.78, 145.62, 138.35, 135.92, 134.25, 124.93, 120.16, 119.50, 119.41, 116.29, 105.46, 59.45, 51.82, 43.35,
42.81, 35.46 and 29.08 ppm; PXRD diffractogram (Figure S16) corresponds to the previously published data [26].

2.3.2. Synthesis of Amorphous Glasdegib Base

Ethyl acetate (60 mL) and 0.5 M sodium hydroxide solution (100 mL) were added to glasdegib monomaleate (2.00 g, 4.08 mmol). The suspension was mixed at 25 °C until no solid particles were observed. The phases were separated, and the organic phase was washed two times with 0.5 M sodium hydroxide solution (2 × 45 mL) and another two times with water (2 × 20 mL). Ethyl acetate phase was dried over sodium sulfate. The solids were filtered off, and the filtrate was concentrated on the rotary evaporator until a solid phase was obtained. The amorphous solid was additionally dried at 40 °C under reduced pressure to obtain 1.30 g (65% yield) of amorphous glasdegib base, which was used directly for the preparation of the crystalline glasdegib base.

2.3.3. Synthesis and Characterization of Crystalline Glasdegib Base

The amorphous glasdegib base (200 mg, 0.534 mmol) was dissolved in mixture of ethyl acetate (40 mL) and methanol (0.6 mL) upon heating to 60 °C using an ultrasonic bath. Clear solution was placed into the vial and stirred at room temperature (25 °C) for about 16 h, with a pierced vial cap to enable slow evaporation of part of the solvent. The resulting solid was filtered and dried at 40 °C under reduced pressure to give 110 mg (55% yield) of crystalline glasdegib base (Figure S20). DSC (10 °K/min): 235.5 °C onset, 237.2 °C peak; FTIR (KBr): 3356, 3051, 2982, 2947, 284, 2793, 2219, 1708, 1659, 1622, 1593, 1456, 1431, 1418, 1380, 1369, 1328, 1271, 1177, 1146, 1146, 1112, 1073, 1042, 1002, 991, 896, 834, 778, 767, 744, 677, 639, 569, 549, 513, 467 and 424 cm⁻¹; Raman: 3353, 3066, 3053, 2982, 2951, 2929, 2897, 2224, 2216, 1709, 1661, 1610, 1592, 1543, 1532, 1451, 1321, 1270, 1230, 1206, 1180, 1147, 1114, 1046, 1028, 1003, 982, 926, 890, 850, 830, 751, 714, 643, 625, 617, 552, 514, 503, 469 and 446 cm⁻¹.

2.3.4. Synthesis and Characterization of Glasdegib Dihydrochloride Hydrate

The glasdegib base (100 mg, 0.267 mmol) was dissolved in mixture of ethyl acetate (17 mL) and methanol (3 mL). The suspension was mixed at 50 °C until it became clear. To the solution, 6 N hydrochloric acid in isopropanol (0.1068 mL) was added. After several minutes, a solid phase was observed. The suspension was cooled down to 5 °C, and the solid particles were filtered and dried at 40 °C under reduced pressure to provide 50 mg (42% yield) of crystalline glasdegib dihydrochloride hydrate [17] (Figure S21). DSC (10 °K/min): 159.1 °C onset, 189.4 °C peak and 208.0 °C onset, 210.7 °C peak; FTIR (KBr): 3314, 3100, 3050, 2928, 2853, 2736, 2613, 2224, 1707, 1629, 1595, 1534, 1486, 1471, 1453, 1430, 1414, 1383, 1325, 1288, 1223, 1175, 1151, 1116, 1064, 1023, 989, 968, 930, 896, 876, 836, 759, 750, 668, 638, 620, 546, 518, 495 and 479 cm⁻¹; Raman: 3087, 3078, 3053, 3024, 2993, 2982, 2974, 2945, 2934, 2227, 2215, 1715, 1706, 1610, 1573, 1545, 1528, 1491, 1453, 1388, 1336, 1317, 1306, 1287, 1266, 1242, 1205, 1176, 1155, 1118, 1101, 1064, 1037, 1019, 1001, 968, 930, 896, 878, 843, 831, 800, 745, 714, 704, 644, 620, 561, 544, 520, 509, 495, 474, 446, 417 and 400 cm⁻¹.

2.3.5. Synthesis and Characterization of Glasdegib Dimaleate

Glasdegib monomaleate (100 mg, 0.22 mmol) and maleic acid (31 mg, 0.27 mmol) were dissolved in a mixture of dichloromethane (1.9 mL) and methanol (0.1 mL) upon heating to 40 °C and with the aid of sonication in an ultrasonic bath. The obtained clear solution was filtered through a 0.45 µm syringe filter into a fresh vial fitted with a stir bar. Under constant mixing, dichloromethane (12 mL) was added to the solution. After 2 h of stirring, a white suspension was formed, which was further stirred at room temperature for approximately 16 h. The precipitate was isolated via filtration, rinsed with dichloromethane (1 mL) and dried for about 16 h at room temperature and under a reduced pressure of about 50 mbar to obtain 60 mg (49% yield) of crystalline the glasdegib dimaleate form (Figure S18). DSC
(10 K/min): 186.0 °C onset, 190.1 °C peak; FTIR (KBr): 3390, 3326, 3274, 3223, 3183, 3149, 3105, 2947, 2868, 2704, 2595, 2215, 1699, 1626, 1536, 1416, 1384, 1355, 1330, 1317, 1291, 1244, 1227, 1176, 1147, 1123, 1096, 1067, 1008, 988, 930, 891, 849, 821, 799, 752, 718, 673, 667, 618, 577, 551, 521, 505, 492, 450 and 427 cm⁻¹; Raman: 3192, 3077, 3049, 2990, 2950, 2926, 2868, 2704, 2595, 2215, 1699, 1602, 1536, 1454, 1381, 1347, 1318, 1292, 1271, 1209, 1176, 1146, 1119, 1110, 1037, 1018, 999, 964, 932, 894, 876, 843, 830, 799, 782, 745, 715, 618 and 486 cm⁻¹; ¹H NMR (MeOD, 500 MHz): δ 7.70–7.63 (m, 2H), 7.59 (s, 4H), 7.40–7.32 (m, 2H), 6.31 (s, 4H), 4.71 (dd, J = 8.9, 4.9 Hz, 1H), 4.26 (t, J = 4.6 Hz, 1H), 3.70 (d, J = 12.9 Hz, 1H), 3.37 (ddd, J = 14.1, 11.3, 8.3 Hz, 1H), 2.74 (s, 3H), 2.52–2.41 (m, 2H), 2.28 (ddt, J = 15.0, 11.0, 4.2 Hz, 1H) and 2.11 (dt, J = 15.2, 4.6 Hz, 1H) ppm; ¹³C NMR (MeOD, 125 MHz, proton-decoupled): δ 169.93, 156.75, 149.89, 145.59, 138.31, 134.24, 133.74, 125.12, 120.16, 119.53, 119.44, 116.36, 105.47, 59.31, 51.86, 43.22, 42.56, 35.16 and 28.83 ppm; PXRD (Cu-Kα): 5.5, 7.7, 9.2, 10.3, 11.0, 11.3, 11.9, 13.8, 14.7, 15.4, 17.0, 17.3, 18.0, 18.6, 19.3, 19.5, 20.8, 22.0, 22.8, 24.6, 25.4, 25.6, 26.0, 26.6, 27.3, 27.9, 29.2 and 29.8° 2θ.

3. Results

3.1. Synthesis of Glasdegib Dimaleate

Initially we conducted an extensive screening of the solid form in order to identify potential novel forms of glasdegib. In the majority of cases, no new solid form was detected. However, when we crystallized glasdegib monomaleate from dichloromethane, we observed that the substance was only partially soluble. Furthermore, after the removal of unsolved material via filtration, a new solid was crystallized from a clear dichloromethane solution. The analyses of the solid via PXRD (Figures 2, S16, S18, S20 and S21) and DSC (Figures S1–S4) suggested that a new form was obtained. Moreover, the solution ¹H NMR analysis of the obtained solid indicated that excess maleic acid was present in a novel form. Therefore, subsequent targeted crystallization experiments using glasdegib monomaleate in the presence of additional quantities of maleic acid provided a new form, which was determined to be glasdegib dimaleate based on the solution ¹H NMR analysis (Figures S27 and S29). In order to improve the process feasibility, due to the low solubility of glasdegib monomaleate in dichloromethane, we conducted subsequent crystallization experiments from the mixture of dichloromethane and methanol, which provided consistently pure glasdegib dimaleate.

Figure 2. Powder X-ray diffraction patterns of glasdegib derivatives: glasdegib base, glasdegib dihydrochloride, glasdegib monomaleate and glasdegib dimaleate.
3.2. Characterization of Glasdegib Dimaleate

3.2.1. PXRD Analysis

As presented in Figures 2 and S18, glasdegib dimaleate had notably different PXRD signal pattern in the PXRD diffractogram compared to the glasdegib monomaleate, glasdegib base or glasdegib dihydrochloride. The PXRD pattern of glasdegib dimaleate contained several characteristic signals at 2-Theta of 7.5°, 15.4°, 20.3°, 20.8°, 22.0°, 24.6°, 25.4°, 25.6° and 26.0°, which were not observed in the glasdegib monomaleate, glasdegib base or glasdegib dihydrochloride. To obtain a more complete picture on the characteristics of this novel form, we performed additional characterization using IR, Raman, DSC, TGA ssNMR and single-crystal X-ray analysis, which is described below.

3.2.2. Infrared Spectral Analysis

In the IR spectrum of glasdegib monomaleate (Figure 3) and glasdegib dimaleate (Figure 4), the region between 3500 and 2500 cm⁻¹ is populated by overlapping N–H, O–H, sp² C–H (benzene rings) and sp³ C–H (CH₂ and CH₃ groups) stretching vibrations. In the case of the monomaleate form, distinct bands are observed at 3424, 3326, 3275, 3188, 3042, 2975, 2912, 2882, 2787 and 2750 cm⁻¹ (Figure 3), while in the case of the dimaleate form, distinct bands are observed at 3326, 3274, 3183, 3105, 3047, 2946, 2868 and 2595 cm⁻¹ (Figure 4). The most diagnostic band in the IR spectra is associated with stretching of the nitrile (C≡N) group, which is located at 2219 cm⁻¹ for the monomaleate form (Figure 3) and at 2215 cm⁻¹ for the dimaleate form (Figure 4). The carbonyl (C=O), alkene (C=C) and aromatic (C=C) stretching vibration regions (ca. 1700–1500 cm⁻¹) are densely populated with bands for the cis-alkene group, aromatic double bonds, the urea carbonyl group, the carboxylic acid carbonyl group and the carboxylate anion carbonyl group. In this region the most diagnostic band is located at 1690 cm⁻¹ for the monomaleate form (Figure 3) and at 1699 cm⁻¹ for the dimaleate form (Figure 4). Similarly, the fingerprint regions or IR spectra for both forms are crowded with a large number of similar absorption bands.

Figure 3. IR spectrum of glasdegib monomaleate with highlighted diagnostic regions and bands.
3.2.3. Raman Analysis

Due to the congested IR spectrum with a large number of overlapping bands in the fingerprint region, we decided to also characterize the glasdegib monomaleate and dimaleate forms using Raman spectroscopy, which should enable better distinction of both forms. The Raman spectrum of glasdegib monomaleate (Figure 5) and glasdegib dimaleate (Figure 6) display CH stretching of unsaturated carbons in the region above 3000 cm$^{-1}$, while CH stretching of saturated carbons popthe ulates the region from 3000 to 2933 cm$^{-1}$ for monomaleate form, and from 3000 to 2950 cm$^{-1}$ for the dimaleate form. The most diagnostic bands (C≡N stretch of a nitrile bond) in the Raman spectra are located at 2219 cm$^{-1}$ for the monomaleate form (Figure 5) and at 2216 cm$^{-1}$ for the dimaleate form (Figure 6). Furthermore, a distinct characteristic band is also observed for the carbonyl group (C=O) at 1691 cm$^{-1}$ for the monomaleate form (Figure 5) and at 1699 cm$^{-1}$ for the dimaleate form (Figure 6). In addition, very strong aryl C=C stretches at 1613 cm$^{-1}$ for the monomaleate form (Figure 5) and 1602 cm$^{-1}$ for the dimaleate form (Figure 6) are observed, and are also detected in the glasdegib base (Figure S13).
3.2.4. DSC and TGA Analysis

The thermal behaviors of the obtained glasdegib dimaleate, glasdegib monomaleate, glasdegib dihydrochloride hydrate [17] and glasdegib base are shown in Figures 7 and S1–S4. It can be observed that the new dimaleate form exhibits distinct thermal behavior compared to the other glasdegib derivatives (Figure 7).

In the DSC thermogram of glasdegib monomaleate (Figure 7, black line and Figure S1) two endothermic transitions were observed. The first transition at 118.5 °C (onset) and 124.8 °C (peak) is associated with a 2.3% mass loss, as observed in the TGA thermogram above 100 °C (Figure S1), which is probably associated with the partial desolvation of the residual solvent. The second broader peak transition at 195.4 °C (onset) and 200.2 °C (peak) is associated with the melting of the monomaleate form. After both endothermic phenomena, an exothermic transition associated with decomposition was not observed up to 300 °C.

Glasdegib dihydrochloride hydrate (Figure 7, red line and Figure S4) exhibited more complex thermal behavior, where a very broad endothermic peak was observed at 159.1 °C (onset) and 189.4 °C (peak). In this endothermic transition, the TGA thermogram (Figure S4) shows that 10.86% of the mass is lost until 206 °C, which probably corresponds to a loss of one hydrochloric acid and one water (calculated mass loss 11.7%). Subsequently, another
endothermic transition is observed at 208.0 °C (onset) and 210.7 °C (peak), which probably corresponds to the melting of the formed hydrochloride form. In the TGA thermogram (Figure S4) it can be observed that additional mass loss starts at temperatures above 215 °C and continues up to the final measured temperature of 300 °C. In this temperature range, the formation of the glasdegib base (see paragraph below) can be observed in the DSC thermogram, which melts at 235.7 °C (onset) and 237.8 °C (peak). Interestingly, at temperatures between 265 and 270 °C, an exothermic transition can be observed, which is not observed in other glasdegib derivatives and is probably associated with decomposition.

The glasdegib base (Figure 7, blue line and Figure S3) has a simple thermogram with a single melting peak at 235.2 °C (onset) and 237.2 °C (peak) and no exothermic transition up to 300 °C. The mass loss for the glasdegib base was observed in the TGA thermogram (Figure S3) above 230 °C and continued until the final measured temperature of 300 °C.

The DSC curve of glasdegib dimaleate (Figure 7, green line and Figure S2) shows no thermal events until the first endothermic peak, with an onset temperature of 165.9 °C and a peak temperature of about 169.3 °C; this indicates the good thermal stability of the glasdegib dimaleate form. Furthermore, no exothermic phenomena are observed in the DSC thermogram up to 300 °C. The TGA thermogram (Figure S2) shows that mass loss for glasdegib dimaleate starts at temperatures above 110 °C.

3.2.5. Solid-State Nuclear Magnetic Resonance Analysis

In order to determine the true ionization state of glasdegib dimaleate, we first conducted an ssNMR study, which involved $^1$H ssNMR as well as $^{15}$N ssNMR measurements using glasdegib monomaleate, glasdegib dihydrochloride and glasdegib bases as key standards for the ionized and unionized state of glasdegib. The glasdegib base presents a reference substance for non-protonated species of glasdegib derivatives, whereas glasdegib dihydrochloride serves as a reference for the protonated double-salt form.

The ssNMR characterization of different glasdegib forms included $^1$H echo MAS (magic-angle spinning) ssNMR spectra, which showed proton signals between $\delta_H$ 14 and 16 ppm for glasdegib ($\delta_H$ 14.6 ppm) as well as dihydrochloride ($\delta_H$ 15.8 ppm) that are most likely involved in intermolecular hydrogen bonds (Figure S26). The signal of dihydrochloride salt appears broader, which could be attributed to the fact that multiple molecules are present per asymmetric unit, as also observed in $^{15}$N ssNMR spectra (vide infra). Glasdegib monomaleate and glasdegib dimaleate showed two sets of signals each: one at $\delta_H$ 14–16 ppm and the other at $\delta_H$ 20 ppm (Figure S26). The latter suggests the formation of additional hydrogen bonds for monomaleate and dimaleate species. A $^1$H ssNMR chemical shift of such high value is typical for strong hydrogen-bond interactions.

The glasdegib base showed four groups of signals in the $^{15}$N CP-MAS ssNMR spectrum (Figure 8a). The lowest NMR chemical shift was assigned to methylpiperidine nitrogen ($\delta_N$ –334.6 ppm). The intense signal at $\delta_N$ –285.7 ppm was attributed to both urea nitrogen atoms, followed by two benzimidazole nitrogen atoms in the region between $\delta_N$ –266.5 and –272.3 ppm (pyrrole-like NH) and at $\delta_N$ –231.0 ppm (pyridine-like N). Similarly, four groups of NMR signals were observed for glasdegib dihydrochloride (Figure 8b). The lowest NMR chemical shift at $\delta_N$ –326.2 ppm was assigned to methylpiperidine nitrogen. The signal at $\delta_N$ –290.1 ppm was attributed to both urea nitrogen atoms, followed by two benzimidazole nitrogen atoms in the regions between $\delta_N$ –268 and –270 ppm (pyrrole-like NH) and between $\delta_N$ –210 and –223 ppm (pyridine-like N). Note that some of the NMR signals in the $^{15}$N CP-MAS spectra of glasdegib dihydrochloride are doubled, which suggests that more than one molecule is present per asymmetric unit (Figure 8b).

Glasdegib dihydrochloride showed a higher intensity of methylpiperidine nitrogen compared to the glasdegib base. Furthermore, the protonation of the methylpiperidine nitrogen atom showed an NMR chemical shift change of ca. 10 ppm (Figure 8a,b).
Figure 8. $^{15}$N CP MAS ssNMR ($^{15}$N cross-polarization magic-angle spinning solid-state nuclear magnetic resonance) spectra of (a) glasdegib base, (b) glasdegib dihydrochloride, (c) glasdegib monomaleate and (d) glasdegib dimaleate.

The $^{15}$N ssNMR spectra of the glasdegib monomaleate and glasdegib dimaleate species were compared to the glasdegib base and dihydrochloride forms (Figure 8). The methylpiperidine nitrogen atoms of both glasdegib monomaleate and glasdegib dimaleate showed $^{15}$N chemical shifts similar to glasdegib dihydrochloride, which suggests the protonation of methylpiperidine nitrogen. A chemical shift of the methylpiperidine nitrogen atom was observed at $\delta_N - 325.2$ ppm for glasdegib monomaleate species (Figure 8c) and at $\delta_N - 326.1$ ppm for glasdegib dimaleate species (Figure 8d). In addition, a small chemical-shift difference was observed for pyridine-like the benzimidazole nitrogen atom when comparing glasdegib monomaleate and glasdegib dimaleate, where dimaleate species showed NMR chemical shifts similar to glasdegib dihydrochloride (compare $^{15}$N NMR signals at ca. $\delta_N - 216$ ppm).

The $^{15}$N LG-CP MAS ssNMR spectra [35–37] were recorded for each glasdegib form, where a short excitation time (200 µs) was used to transfer polarization from the $^1$H to $^{15}$N nuclei. The comparison with the CP MAS spectra of glasdegib derivatives allowed enabled the detection of protonated and unprotonated species (Figure 9). The $^{15}$N ssNMR chemical shift of the glasdegib base is consistent with the non-protonated form, as no signal could
be observed for the methylpiperidine nitrogen atom at ca. $\delta_N \approx -335$ ppm (Figure 9a). The NMR signals of other nitrogen atoms (urea and benzimidazole nitrogens) were observed at the same chemical shifts as in the $^{15}$N CP-MAS spectra (compare Figures 8a and 9a).

The $^{15}$N LG-CP MAS ssNMR spectra confirmed that both monomaleate and dimaleate species correspond to protonated forms of glasdegib (Figures 9c and 9d, respectively). Strong $^{15}$N NMR signals were observed for methylpiperidine nitrogen atoms in the case of glasdegib monomaleate at $\delta_N \approx -325.8$ ppm (Figure 9c) as well as in the case of glasdegib dimaleate at $\delta_N \approx -326.4$ ppm (Figure 9d). Furthermore, the pyridine-like benzimidazole nitrogen atom of glasdegib monomaleate species showed a negligible shift when compared to the glasdegib base ($\delta_N \approx -227.7$ ppm; $\Delta \delta_N$ 3 ppm), which suggests that glasdegib monomaleate exists in salt form with its primary protonation site on the methylpiperidine nitrogen atom. Glasdegib dimaleate showed an identical deshielded methylpiperidine nitrogen atom, and interestingly, a remarkable shift in the pyridine-like benzimidazole nitrogen atom ($\delta_N \approx -216$ ppm; $\Delta \delta_N$ 15 ppm) with respect to the glasdegib base.

Figure 9. $^{15}$N LG-CP MAS ssNMR ($^{15}$N Lee–Goldburg cross-polarization magic-angle spinning solid-state nuclear magnetic resonance) spectra of (a) glasdegib base, (b) glasdegib dihydrochloride, (c) glasdegib monomaleate and (d) glasdegib dimaleate. Note that signals marked with * were attributed to artefacts that correspond to transmitter-frequency offset.
In essence, the salt/co-crystal properties of glasdegib monomaleate were assessed by comparing its $^{15}$N chemical shifts to the glasdegib base and dihydrochloride species. The methylpiperidine nitrogen atoms of glasdegib monomaleate exhibit $\delta_N = -325.8$ ppm, which is consistent with the downfield shift of ca. 10 ppm, as observed in the case of glasdegib dihydrochloride. Additionally, the pyridine-like benzimidazole nitrogen atom of the glasdegib monomaleate species showed a negligible shift when compared to the glasdegib base ($\Delta\delta_N = 3$ ppm), which suggests that glasdegib monomaleate exists in salt form with its primary protonation site on the methylpiperidine nitrogen atom. Glasdegib dimaleate showed a remarkable shift in the pyridine-like benzimidazole nitrogen atom ($\Delta\delta_N = 15$ ppm). The latter implies that despite the low $\Delta pK_a$ value for the benzimidazole nitrogen/maleic acid pair, the obtained glasdegib dimaleate exists in double-salt form.

3.2.6. X-ray Single-Crystal Determination

We were able to obtain crystals of glasdegib monomaleate and glasdegib dimaleate suitable for the X-ray structural analysis (Figure 10a,b). The crystallographic data are listed in Table 1. In both crystal structures, partially deprotonated maleic acid is present in the form of maleate monoanions with a strong intramolecular O–H· · ·O hydrogen bond (2.386(4)–2.403(2) Å). The C–O distances are within the ranges expected for maleate monoanion.

Figure 10. Thermal ellipsoid figures of (a) glasdegib monomaleate and (b) glasdegib dimaleate drawn at the 30% probability level. The asymmetric unit of glasdegib monomaleate contains one protonated glasdegib molecule and one maleate monoanion. The asymmetric unit of glasdegib dimaleate contains one double-protonated glasdegib molecule and two maleate monoanions. Hydrogen bonds are represented by dashed blue lines.

Compound glasdegib monomaleate crystallizes in monoclinic space group $P2_1$ with one protonated glasdegib molecule and one maleate monoanion in an asymmetric unit (Figure 10a).
The glasdegib molecule is protonated on the methylpiperidine N4 nitrogen atom. In glasdegib monomaleate, a hydrogen-bonded chain is formed along the c axis through a series of interactions between a protonated glasdegib molecule and a maleate monoanion (Figure 11). The methylpiperidine NH group of glasdegib is connected to maleate via N4–H4···O2 hydrogen bonding and supported by a C23–H23···N5 interaction between maleate and a benzimidazole moiety, forming an R^2_2(9) ring motif [38]. Furthermore, glasdegib interacts with the adjacent maleate monoanion through N1–H1···O3^i and N6–H6a···O5^i interactions with urea and benzimidazole moieties, respectively, supported by C3–H3···O2^i and C12–H12···O4^i bonding and forming one R^2_2(12) and two R^2_2(8) ring motifs (symmetry code: (i) x, y, 1+z) (Table 2). The chains are connected into layers along the bc plane through C18–H18···O1^iii interactions between the benzimidazole moiety and the urea oxygen atom (symmetry code: (iii) x, 1+y, z) (Figure 11a). Double layers are formed through C11–H11b···N3^ii interaction, connecting the methylpiperidine moiety of one glasdegib molecule with the cyano-group of the adjacent glasdegib molecule (symmetry code: (ii) 1−x, 1/2+y, 2−z) (Figure 11b,c).

Figure 11. Hydrogen-bond architecture in the glasdegib monomaleate: (a) layer formation along bc plane; (b) formation of double layers via C11–H11b···N3 interactions; (c) packing of double layers along a axis (arbitrary colors; one double layer is presented by light and dark blue and second double layer is represented by light and dark magenta). Hydrogen bonds are represented by dashed blue lines. Hydrogen atoms not involved in the motif shown have been omitted for clarity.
The benzimidazole moiety interacts with one maleate monoanion (symmetry code: (iii) (Figure 12a, Table 2). The methylpiperidine moiety of the glasdegib dication is connected to one maleate anion via parallel π interactions between the phenyl rings of the cyanophenyl and benzimidazole moieties.

Hydrogen bonds for glasdegib monomaleate and glasdegib dimaleate [Å and °].

| D–H · · · A | d(D–H) | d(H···A) | d(D···A) | <(DHA) |
|------------|--------|--------|--------|--------|
| N1–H1···O3 | 0.885(13) | 2.033(15) | 2.892(2) | 164(2) |
| N4–H4···O2 | 0.98(2) | 1.78(3) | 2.687(2) | 151(2) |
| N6–H6···O5 | 0.90(3) | 1.87(3) | 2.762(2) | 171(3) |
| O3–H3A···O4 | 1.16(3) | 1.25(3) | 2.403(2) | 177(3) |
| C3–H3···O2 | 0.95 | 2.54 | 3.438(3) | 162.7 |
| C7–H7···O1 | 0.95 | 2.25 | 3.683(3) | 121.7 |
| C11–H11B···N3ii | 0.99 | 2.42 | 3.407(3) | 172.5 |
| C12–H12···O4 | 1.00 | 2.25 | 3.211(2) | 161.9 |
| C18–H18···O1ii | 0.95 | 2.56 | 3.302(3) | 135.2 |
| C23–H23···N5 | 0.95 | 2.54 | 3.274(3) | 134.3 |

Symmetry codes for glasdegib monomaleate: (i) x, y, 1 + z; (ii) 1 − x, 1 − y, 1 − z; (iii) x, 1 + y, z, and for glasdegib dimaleate: (i) 1/2 − x, 1 − y, 1/2 + z; (ii) 1 − x, −1/2 + y, 1/2 − z; (iii) x, y, −1 + z.

Compound glasdegib dimaleate crystallizes in orthorhombic space group P212121 with one double-protonated glasdegib molecule and two maleate monoanions in an asymmetric unit (Figure 10b). The glasdegib molecule is protonated on the methylpiperidine N4 nitrogen atom as well as on the benzimidazole N5 nitrogen atom. A small structural difference between the monoprotonated vs. diprotonated glasdegib molecule is evident due to the benzimidazole moiety as well as on the benzimidazole N5 nitrogen atom. A small structural difference between the double-protonated glasdegib molecule and two maleate anions in an asymmetric unit (Figure 10b). The glasdegib molecule is protonated on the methylpiperidine N4 nitrogen atom as well as on the benzimidazole N5 nitrogen atom. A small structural difference between the monoprotonated vs. diprotonated glasdegib molecule and two maleate anions in an asymmetric unit (Figure 10b). The glasdegib molecule is protonated on the methylpiperidine N4 nitrogen atom as well as on the benzimidazole N5 nitrogen atom. A small structural difference between the double-protonated glasdegib molecule and two maleate anions in an asymmetric unit (Figure 10b).

The methylpiperidine moiety of the glasdegib dication is connected to one maleate anion via N4–H4···O2 hydrogen bonding, and this maleate anion is further connected to the adjacent glasdegib dication through N1–H1···O4i and N2–H2···O5i interactions with the urea moiety supported by a C12–H12···O5i interaction with the methylpiperidine moiety, forming R21(8) and R12(7) ring motifs (symmetry code: (i) 1/2 − x, 1 − y, 1/2 + z) (Figure 12a, Table 2). The benzimidazole moiety interacts with one maleate anion through bifurcated N5–H5···O6 and N5–H5···O7 hydrogen bonding, supported by C13–H13b···O6 and C21–H21···O7 interactions; thus, each oxygen atom (O6 and O7) is an acceptor of two hydrogen bonds, and R12(7), R12(6) and R12(4) ring motifs are formed. Furthermore, the benzimidazole moiety also interacts with the adjacent maleate monoanion through bifurcated N6–H6···O8i and N6–H6···O9i hydrogen bonding, forming an R12(4) ring motif. This maleate anion also supports the formation of the chain through a C28–H28···N3iii interaction with the cyano-group of the adjacent glasdegib dication (symmetry code: (iii) x, y, −1 + z). Chain formation is also further supported by almost-parallel π···π interactions between the phenyl rings of the cyano phenyl and benzimidazole moieties of two adjacent molecules, with a centroid-to-centroid distance of 3.9040(18) Å.
and ring slippage of 1.413 Å. A supramolecular structure is achieved, connecting the chains via C9–H9···O5\textsuperscript{ii} interactions (symmetry code: (ii) 1 − x, −y, 1/2 + z) (Figure 12b,c).

Figure 12. Hydrogen-bond architecture in the glasdegib dimaleate: (a) chain formation along c axis; (b) packing of chains along ab plane via C9–H9···O5 interactions; (c) space-filled presentation of packing of chains (arbitrary colors). Hydrogen bonds are represented by dashed blue lines and π···π interactions by dashed green lines. Hydrogen atoms not involved in the motif shown have been omitted for clarity.

The crystal structures of glasdegib monomaleate and glasdegib dimaleate differ primarily in their glasdegib:maleate monoanion ratios and in a charge on the glasdegib species. In glasdegib monomaleate, each protonated glasdegib molecule is hydrogen-bonded to two adjacent maleate monoanions, forming a chain along the c axis, primarily through N–H···O interactions. In glasdegib dimaleate, each double-protonated glasdegib molecule is hydrogen-bonded to four adjacent maleate monoanions, forming a chain along the c axis, also primarily through N–H···O interactions. Monoprotonated and diprotonated glasdegib species differ in their number of potential NH hydrogen-bond donating sites as well as in their N hydrogen-bond acceptor sites. Different hydrogen-bonding patterns can be observed due to the different behavior of urea NH groups. In glasdegib monomaleate, only one urea NH group is involved in hydrogen bonding, while both urea NH groups are hydrogen-bond donors in glasdegib dimaleate. The urea oxygen atom is in both crystal structures involved only in intramolecular hydrogen bonding. In both structures, the methylpiperidine N atom is protonated and is involved in strong N–H···O interactions with maleate monoanion. The main difference regarding hydrogen-bond donor/acceptor sites lies in the benzimidazole group. Nitrogen atom N5 is protonated only in glasdegib dimaleate; thus, the benzimidazole moiety possesses two NH groups as a hydrogen-bond
donor. Contrarily, in glasdegib monomaleate, benzimidazole possesses only one NH group acting as hydrogen-bond donor and one N atom acting as hydrogen-bond acceptor. In glasdegib monomaleate, four NH groups form three N–H⋯O interactions with maleate monoanion, while in glasdegib dimaleate, five NH groups form seven N–H⋯O interactions, with four being bifurcated. A higher number of hydrogen-bonding interactions in the dimaleate form potentially explains the slightly higher stability of this form. Even though in glasdegib dimaleate, two monoanionic maleate ions are present and the glasdegib is double-protonated, as well as possessing a higher number of hydrogen-donating sites, there is an almost negligible difference in the conformation of mono- vs. diprotonated glasdegib species (Figure 13a). Although their conformations are similar, their intermolecular interactions still lead to different packing arrangements; this is already shown by the fact that glasdegib monomaleate and glasdegib dimaleate crystallize in monoclinic and orthorhombic space groups, respectively. In glasdegib monomaleate, the protonated glasdegib molecules are arranged in a head-to-head fashion, while in glasdegib dimaleate, the double-protonated glasdegib molecules are arranged in a head-to-tail fashion (Figure 13b).

Figure 13. Superposition showing the differences in the conformation of glasdegib monomaleate (orange) and glasdegib dimaleate (green) of (a) glasdegib molecule and (b) chains along c axes, formed primarily by N–H⋯O interactions. Maleate monoanions are presented in light orange and light green colors.

3.2.7. Stability Testing
To gain initial insights into the stability of glasdegib dimaleate, we conducted preliminary comparative stress testing with glasdegib monomaleate in a 3-month study. The stress stability testing of both glasdegib monomaleate and glasdegib dimaleate was conducted under storage conditions of 40 °C and 75% RH (open dish). Both samples were analyzed for purity and chiral purity using liquid chromatography methods at four time points: initially (t = 0), and after each month and was completed after 3 months (Table 3). In addition, solid-form purity was also checked using PXRD.
Table 3. Stability of glasdegib monomaleate and glasdegib dimaleate.

| Form Type and Testing Time Point | Chiral Purity ¹ [Area%] | Purity ² [Area%] |
|---------------------------------|------------------------|-----------------|
| glasdegib monomaleate, t = 0    | 100.00                 | 99.86           |
| glasdegib monomaleate, t = 1 month | 99.96               | 99.81           |
| glasdegib monomaleate, t = 2 months | 99.96               | 99.73           |
| glasdegib monomaleate, t = 3 months | 99.96               | 99.72           |
| glasdegib dimaleate, t = 0     | 100.00                 | 99.98           |
| glasdegib dimaleate, t = 1 month | 100.00               | 99.97           |
| glasdegib dimaleate, t = 2 months | 100.00               | 99.93           |
| glasdegib dimaleate, t = 3 months | 100.00               | 99.90           |

¹ Determined via chiral HPLC method. ² Determined via UHPLC method.

The testing results of both glasdegib monomaleate and glasdegib dimaleate indicated that both forms are stable in terms of chiral purity, indicating that the previously reported epimerization of the dihydrochloride form to (25,4R)-epimer [26] does not take place in either maleate form in a solid state. Interestingly, the study showed that the monomaleate form is chemically slightly less stable, as evidenced by the analysis of UHPLC purity, where a slightly higher rise in degradation products was observed for glasdegib monomaleate (purity dropped from a 99.86 area% at the beginning of the testing to a 99.72 area% after 3 months; Δ(Σ impurities) = 0.14%) compared to glasdegib dimaleate (purity dropped from 99.98 area% at the beginning of the testing to 99.90 area% after 3 months; Δ(Σ impurities) = 0.08%). The results obtained using the PXRD measurements indicated that glasdegib dimaleate is fully stable for at least 2 months at 40 °C and 75% RH (Figure S22), while in the case of glasdegib monomaleate, traces of glasdegib dimaleate were already observed after 1 month (Figure S23).

3.2.8. Solubility Testing

The dissolution and solubility of glasdegib monomaleate and glasdegib dimaleate were evaluated at a pH of 1.2, 4.0, 5.5 and 7.0 using the United States Pharmacopeia and European Pharmacopoeia buffers.

At pH = 1.2 (Figure 14), similar dissolution behavior was observed for both the mono and dimaleate form, with solubility slightly rising over the time. After 24 h, glasdegib monomaleate had slightly higher solubility (11.08 mg/mL) compared to the glasdegib dimaleate (10.62 mg/mL).

![Figure 14. Dissolution testing of glasdegib monomaleate and glasdegib dimaleate at pH = 1.2.](image-url)
At pH = 4.0 (Figure 15), the dissolution curves were different compared to those obtained at pH = 1.2. In this case, the solubility of both forms was dropping over time. After 24 h, glasdegib monomaleate had higher solubility (2.56 mg/mL) compared to the glasdegib dimaleate (1.68 mg/mL).

![Figure 15. Dissolution testing of glasdegib monomaleate and glasdegib dimaleate at pH = 4.0.](image)

At pH = 5.5 (Figure 16) the dissolution curves were similar compared to those obtained at pH = 1.2, slightly rising over time. After 24 h, glasdegib dimaleate had higher solubility (3.02 mg/mL) compared to the glasdegib monomaleate (2.28 mg/mL).

![Figure 16. Dissolution testing of glasdegib monomaleate and glasdegib dimaleate at pH = 5.5.](image)

At pH = 7.0 (Figure 17), the dissolution curves revealed that solubility was rising slightly over time after 4 h for both forms. After 24 h, glasdegib monomaleate had slightly lower solubility (0.76 mg/mL) compared to the glasdegib dimaleate (0.79 mg/mL).

![Figure 17. Dissolution testing of glasdegib monomaleate and glasdegib dimaleate at pH = 7.0.](image)
Figure 17. Dissolution testing of glasdegib monomaleate and glasdegib dimaleate at pH = 7.0.

4. Discussion

The formation of novel maleic acid containing a solid form of glasdegib was confirmed via PXRD, IR, Raman and DSC analysis. Indeed, notable differences in the PXRD diffractogram (Figure 2), IR and Raman spectra (Figures 3–6), as well as in the DSC thermograms, were observed (Figure 7) between the known glasdegib monomaleate form and the novel form. As revealed by the solution $^1$H NMR analysis, the novel solid form had 2:1 stoichiometry between maleic acid and glasdegib. However, the determined stoichiometry of the formed solid brought some ambiguity related to the ionization state of the novel form.

In the past, the $pK_a$ difference between base and acid ($\Delta pK_a = pK_a^{\text{protonated base}} - pK_a^{\text{acid}}$) was established as one of the key parameters that defines the likelihood of salt formation. In general, it is considered that complexes with $\Delta pK_a > 4$ form as salts, while $\Delta pK_a < -1$ favors co-crystal formation. In the interim zone where $-1 < \Delta pK_a < 4$, both types of species can be formed. Nevertheless, the likelihood of co-crystal formation is higher in the lower part of the scale close to or below $\Delta pK_a = 0$ [39]. In the zone where $\Delta pK_a$ is between 0 and 3, a continuum between neutral and ionized species exits, which can provide acid–base complexes with mixed ionization states [40]. Very recently, such evidence was provided experimentally using ssNMR [41] and single-crystal X-ray determination [42] in the pharmaceutical field on tenofovir alafenamide fumarate.

Glasdegib contains two basic sites that can be protonated by an acid: methylpiperidine nitrogen and benzimidazole nitrogen (Figure 1). The reported $pK_a$ values of glasdegib (6.1 for methylpiperidine nitrogen and 1.7 for benzimidazole nitrogen) [24,25] and maleic acid ($pK_{a1} = 1.9$ and $pK_{a2} = 6.3$) [29] give $\Delta pK_a$ values of 4.2 in the case of the methylpiperidine nitrogen/maleic acid pair and $-0.2$ for the benzimidazole nitrogen/maleic acid pair (more acidic proton in maleic acid is considered; Table 4). The reported $pK_a$ values for glasdegib [24,25] do not provide information on which solvent they acquired, which brings some ambiguity to the $\Delta pK_a$ calculation, because $pK_a$ values change in different solvents. Therefore, we also calculated the $pK_a$ values for glasdegib and maleic acid using the ChemAxon Marvin Suite [43] in order to obtain solvent bias-free $pK_a$ and $\Delta pK_a$ values. The calculation using the ChemAxon Marvin Suite provided $pK_a$ values of 6.67 (methylpiperidine nitrogen) and 3.01 (benzimidazole nitrogen) for glasdegib, while $pK_a$ values of 2.85 and 5.75 were obtained for maleic acid. The calculated $pK_a$ values were 3.82 in the case of the methylpiperidine nitrogen/maleic acid pair and 0.16 for the benzimidazole nitrogen/maleic acid pair (Table 4). Thus, the calculated $pK_a$ data fit well
with the measured data, and the obtained $\Delta pK_a$ values are similar for the reported and calculated values.

Table 4. Calculated $\Delta pK_a$ values for glasdegib–maleic acid complex considering glasdegib methylpiperidine nitrogen/maleic acid pair and benzimidazole nitrogen/maleic acid pair.

| $pK_a$ Protonated Base | $pK_{a1}$ Acid [29] | $\Delta pK_a = pK_a$ (Protonated Base) $-$ $pK_{a1}$ (Acid) ** [39] |
|------------------------|---------------------|------------------------------------------------------------------|
| 6.1 (methylpiperidine nitrogen) [24,25] | 1.9 [29] | 4.2 |
| 1.7 (benzimidazole nitrogen) [24,25] | 1.9 [29] | $-0.2$ |
| 6.67 (methylpiperidine nitrogen) * [43] | 2.85 * [43] | 3.82 |
| 3.01 (benzimidazole nitrogen) * [43] | 2.85 * [43] | $0.16$ |

* Calculated using ChemAxon Marvin Suite 17.28.0. ** Calculation performed for more acidic proton in maleic acid.

Based on the calculated $\Delta pK_a$ values for the glasdegib–maleic acid pair, it is obvious that in the case of glasdegib monomaleate, salt will be formed on methylpiperidine nitrogen because $\Delta pK_a = ca. 4$ (Table 4). A similar situation can be anticipated in the case of glasdegib dimaleate, where one maleic acid will protonate the methylpiperidine nitrogen, whereas the second maleic acid could either act as a co-former to form a co-crystal, or form a salt with the benzimidazole nitrogen of glasdegib. The calculated probability for the formation of salt on the benzimidazole nitrogen $P(A^- B^+)$ with the second maleic acid using Cruz-Cabeza equations [39] show that benzimidazole nitrogen should remain unprotonated (the probability of salt formation only 25–31%, Table 5), while the probability of co-crystal formation $P(AB)$ is three times higher (Table 5). Therefore, the obtained glasdegib dimaleate should be a mixture of salt and co-crystal species: $(\text{maleic acid})^- \cdot (\text{maleic acid})^- \cdot (\text{glasdegib})^+ = A^- AB^+$, rather than a double-salt form: $(\text{maleic acid})^- \cdot (\text{maleic acid})^- \cdot (\text{glasdegib})^{2+} = A^- A^- B^{2+}$ (Table 5).

Table 5. Calculated probability for salt or co-crystal formation for the protonation of benzimidazole nitrogen with the second maleic acid molecule in the glasdegib–maleic acid 1:2 complex.

| $\Delta pK_a$ | $P(A^- B^+)$ ¹ (%) | $P(AB)$ ¹ (%) |
|--------------|-------------------|--------------|
| Reported $pK_a$ values. | $-0.2$ | 24.6 | 75.4 |
| Calculated $pK_a$ values | 0.16 | 30.7 | 69.3 |

¹ Calculated probability (P) value based on Cruz-Cabeza equations [39]: $P (AB, \%) = -17 \cdot \Delta pK_a + 72$ and $P (A^- B^+, \%) = 17 \cdot \Delta pK_a + 28$.

To further confirm the structure of glasdegib monomaleate and glasdegib dimaleate, a single-crystal X-ray analysis of both forms was performed. As expected, it confirmed that glasdegib monomaleate exists in salt form with protonated methylpiperidine nitrogen. In the case of glasdegib dimaleate, it affirmed an interesting observation from the $^{15}N$ ssNMR study that this complex exists as a double salt with protonated methylpiperidine nitrogen and benzimidazole nitrogen.

The confirmed double-salt structure $(A^- A^- B^{2+})$, instead of a salt–co-crystal species structure $(A^- AB^+)$, for glasdegib dimaleate by $^{15}N$ ssNMR and single-crystal X-ray analysis is surprising based on the $pK_a$ values of this acid–base pair. This outcome might be attributed to the specific choice of solvents used in the preparation of glasdegib dimaleate, since it is known that the proton transfer process can be solvent-dependent [44] and the choice of solvent plays a very important role in the synthesis of organic salts [45].

Until 2006, the maleate anion was used in 4.2% of marketed drugs containing basic active pharmaceutical ingredients [46]. Similarly, in the period of 2007–2016, the maleate anion was used in 4.3% of drugs that contained basic active pharmaceutical ingredients [47]. Some recent or well-known examples of marketed drugs that contain a maleate anion [48] are afatinib dimaleate (contains two basic sites with $pK_a$ values of 8.2 and 5.0) [49], neratinib monomaleate (contains two basic sites with $pK_a$ values of 7.65 and 4.66) [50], sunitinib
monomaleate (contains one basic site with a pKₐ of 8.95) [51] and enalapril monomaleate
(contains one basic site with a pKₐ of 5.5) [52]. These data suggest that the maleate anion
is used in active pharmaceutical ingredients that contain basic moieties with a pKₐ of
5 or higher, which facilitates salt-species formation. In this respect, glasdegib dimaleate
represents an unusual example.

After the determination of the ionization state of glasdegib dimaleate by ¹⁵N ssNMR
and single-crystal X-ray determination, the physiochemical properties of glasdegib di-
maleate were investigated. The stress stability testing at 40 °C and 75% relative humidity
demonstrated slightly better chemical and physical stability of glasdegib dimaleate com-
pared to the monomaleate form. Moreover, dissolution testing and solubility determination
at pH values of 1.2 (Figure 14) and 7.0 (Figure 17) showed good comparability of both
forms, while lower solubility of dimaleate was observed at a pH of 4.0 (Figure 15) and
higher solubility was observed at a pH of 5.5 (Figure 16). These properties of glasdegib
dimaleate ascertain its suitability for the development of pharmaceutical dosage forms.

5. Conclusions

In summary, for the first time, glasdegib dimaleate was prepared and fully charac-
terized using spectroscopic and thermal analyses, which demonstrated that glasdegib
dimaleate exists in double-salt form. This is a surprising finding based on the known pKₐ
values of glasdegib and maleic acid in the literature. This comparative study of the physico-
chemical properties of both forms suggested that glasdegib dimaleate has similar aqueous
solubility and slightly better stability under stress conditions. These properties affirm
the glasdegib dimaleate form as a suitable candidate for the development of pharmaceutical
preparation. Finally, the presented study demonstrates how unpredictable the formation of
a specific pharmaceutical solid can be in terms of its chemical structure.

6. Patents

This work is based on our International Patent Application WO 2021191278 A1,
30 September 2021.

Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/pharmaceutics14081641/s1, Figure S1: DSC and TGA thermo-
gram of glasdegib monomaleate; Figure S2: DSC and TGA thermogram of glasdegib dimaleate;
Figure S3: DSC and TGA thermogram of glasdegib base; Figure S4: DSC and TGA thermogram of glas-
degib dihydrochloride hydrate; Figure S5: IR spectrum of glasdegib monomaleate, 1800–400 cm⁻¹;
Figure S6: IR spectrum of glasdegib dimaleate, 1800–400 cm⁻¹; Figure S7: IR spectrum of glasdegib
base, 4000–400 cm⁻¹; Figure S8: IR spectrum of glasdegib base, 1800–400 cm⁻¹; Figure S9: IR spec-
trum of glasdegib dihydrochloride hydrate, 4000–400 cm⁻¹; Figure S10: IR spectrum of glasdegib
dihydrochloride hydrate, 1800–400 cm⁻¹; Figure S11: IR spectrum of maleic acid, 4000–400 cm⁻¹;
Figure S12: IR spectrum of maleic acid, 1800–400 cm⁻¹; Figure S13: Raman spectrum of glas-
degib base; Figure S14: Raman spectrum of glasdegib dihydrochloride; Figure S15: Raman spec-
trum of maleic acid; Figure S16: Measured PXRD pattern of glasdegib monomaleate powder;
Figure S17: Calculated PXRD pattern from the single-crystal structure of glasdegib monomaleate;
Figure S18: Measured PXRD pattern of glasdegib dimaleate powder; Figure S19: Calculated PXRD
pattern from the single-crystal structure of glasdegib dimaleate; Figure S20: Measured PXRD pattern
of glasdegib base powder; Figure S21: Measured PXRD pattern of glasdegib dihydrochloride powder;
Figure S22: Measured PXRD pattern of glasdegib dimaleate powder exposed to stress conditions for
2 months; Figure S23: Measured PXRD pattern of glasdegib monomaleate powder exposed to stress
conditions for 1 month; Figure S24: Ultra-high-performance liquid chromatogram of glasdegib for
determination of solubility; Figure S25: Chiral high-performance liquid chromatogram for determination
of chiral purity; Figure S26: ¹H echo MAS NMR spectra of glasdegib base, glasdegib dihydrochloride
hydrate, glasdegib monomaleate and glasdegib dimaleate; Figure S27: ¹H-NMR spectrum of glas-
degib monomaleate in MeOD at 500 MHz; Figure S28: ¹³C-NMR spectrum of glasdegib monomaleate
in MeOD at 125 MHz; Figure S29: ¹H-NMR spectrum of glasdegib dimaleate in MeOD at 500 MHz;
Figure S30: ¹³C-NMR spectrum of glasdegib dimaleate in MeOD at 125 MHz; Figure S31: MarvinS-
ketch 17.28 calculated pKa values for glasdegib; Figure S32: MarvinSketch 17.28 calculated pKa values for maleic acid. CCDC 2180664 and 2180665 contain the supplementary crystallographic data for this paper. These data can be obtained free-of-charge via www.ccdc.cam.ac.uk/data_request/cif, by emailing data_request@ccdc.cam.ac.uk or by contacting The Cambridge Crystallography Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44-1223-336033.

Author Contributions: Conceptualization, B.P. and Z.Č.; methodology, B.P., D.M., F.P., J.P., Z.K., J.C. and Z.Č.; data curation, B.P., D.M., F.P., Z.K., J.C. and J.P.; funding acquisition, Z.Č.; formal analysis B.P., D.M., F.P., Z.K., J.C. and J.P.; investigation, B.P., D.M., F.P., Z.K., J.C. and J.P.; project administration, Z.Č.; resources, Z.Č.; supervision, Z.Č.; validation, B.P., D.M., F.P., Z.K., J.C. and J.P.; visualization, D.M., F.P., J.P. and Z.Č.; writing—original draft, D.M., F.P., J.P. and Z.Č.; writing—review and editing, B.P., D.M., F.P., J.P., Z.K., J.C. and Z.Č. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Lek a Sandoz company.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The authors gratefully acknowledge Z. Ham for the PXRD measurements; M. Crugelj for the solution 1H- and 13C-NMR measurements; H. Cimerman and L. Kolenc for the IR, Raman and thermal analysis measurements; K. Gosak for the conducting the synthesis of the analytical standards of glasdegib diastereomeric impurities; and M. Jazbec for their assistance in the glasdegib dimaleate preparation. We thank the EN-FIST Centre of Excellence, Ljubljana, Slovenia, for use of their SuperNova diffractometer.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of the data; in the writing of the manuscript; or in the decision to publish the results.

References

1. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Acute Myeloid Leukemia Treatment (PDQ®)—Patient Version; National Cancer Institute, Rockville, MD, USA. 2022. Available online: https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq (accessed on 29 July 2022).

2. Ling, Y.; Zhang, Z.; Zhang, H.; Huang, Z. Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges. Curr. Pharm. Des. 2017, 23, 4303–4310. [CrossRef] [PubMed]

3. Ferguson, F.; Gray, N. Kinase inhibitors: The road ahead. Nat. Rev. Drug Discov. 2018, 17, 353–377. [CrossRef] [PubMed]

4. Fiorentini, A.; Capelli, D.; Saraceni, F.; Menotti, D.; Poloni, A.; Olivieri, A. The time has come for targeted therapies for AML: Lights and shadows. Oncol. Ther. 2020, 8, 13–32. [CrossRef] [PubMed]

5. Yu, J.; Jiang, P.Y.Z.; Sun, H.; Zhang, X.; Jiang, Z.; Li, Y.; Song, Y. Advances in targeted therapy for acute myeloid leukemia. Biomark. Res. 2020, 8, 17. [CrossRef] [PubMed]

6. Carter, J.L.; Hege, K.; Yang, J.; Kalpage, H.A.; Su, Y.; Edwards, H.; Hüttemann, M.; Taub, J.W.; Ge, Y. Targeting multiple signaling pathways: The new approach to acute myeloid leukemia therapy. Signal Transduct. Target. Ther. 2020, 5, 288. [CrossRef] [PubMed]

7. Griffiths, E.A.; Carraway, H.E.; Chandhok, N.S.; Prebet, T. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. Leuk. Res. 2020, 91, 106339. [CrossRef] [PubMed]

8. Megías-Vericat, J.E.; Martínez-Cuadrón, D.; Solana-Altabella, A.; Montesinos, P. Precision medicine in acute myeloid leukemia: Where are we now and what does the future hold? Expert Rev. Hematol. 2020, 13, 1057–1065. [CrossRef]

9. Himmelstein, G.; Mascarenhas, J.; Marcellino, B.K. Alternatives to intensive treatment in patients with AML. Clin. Adv. Hematol. Oncol. 2021, 19, 526–535. Available online: https://www.hematologyandoncology.net/archives/august-2021/alternatives-to-intensive-treatment-in-patients-with-aml/ (accessed on 31 July 2022).

10. Attwood, M.M.; Fabbro, D.; Sokolov, A.V.; Knapp, S.; Schöth, H.B. Trends in kinase drug discovery: Targets, indications and inhibitor design. Nat. Rev. Drug Discov. 2021, 20, 839–861. [CrossRef]

11. Yeoh, Z.H.; Bajel, A.; Wei, A.H. New drugs bringing new challenges to AML: A brief review. J. Pers. Med. 2021, 11, 1003. [CrossRef]

12. Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacol. Res. 2021, 165, 105463. [CrossRef]

13. Solana-Altabella, A.; Ballesta-López, O.; Megías-Vericat, J.E.; Martínez-Cuadrón, D.; Montesinos, P. Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. Expert Opin. Emerg. Drugs 2022, 27, 1–18. [CrossRef]

14. Kayser, S.; Levis, M.J. Updates on targeted therapies for acute myeloid leukaemia. Br. J. Haematol. 2022, 196, 316–328. [CrossRef]
15. Ayala-Aguilera, C.C.; Valero, T.; Lorente-Macias, A.; Baillache, D.J.; Croke, S.; Unciti-Broceta, A. Small molecule kinase inhibitor drugs (1995–2021): Medical indication, pharmacology, and synthesis. J. Med. Chem. 2022, 65, 1047–1131. [CrossRef]
16. Jones, C.S.; LaGreca, S.; Li, Q.; Munchhof, M.J.; Reiter, L.A. Benzimidazole Derivatives. International Patent Application WO 20004427 A2, 8 January 2009.
17. Munchhof, M.J.; Li, Q.; Shavnya, A.; Borzillo, G.V.; Boyden, T.L.; Jones, C.S.; LaGreca, S.D.; Martinez-Alsina, L.; Patel, N.; Pelletier, K.; et al. Discovery of PF-0449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med. Chem. Lett. 2012, 3, 106–111. [CrossRef]
18. Peng, Z.; Wong, J.W.; Hansen, E.C.; Puchlopek-Dermenci, A.L.A.; Clarke, H.J. Development of a concise, asymmetric synthesis of a smoothened receptor (SMO) inhibitor. Enzymatic transamination of a 4-piperidinone with dynamic kinetic resolution. Org. Lett. 2014, 16, 860–863. [CrossRef]
19. Gras, J.G. Hedgehog signaling inhibitor, treatment of myelodysplastic syndrome, treatment of chronic myelomonocytic leukemia, treatment of acute myeloid leukemia, treatment of myelofibrosis. Drugs Future 2017, 42, 265–274. [CrossRef]
20. Hoy, S.M. Glasdegib: First Global Approval. Drugs 2019, 79, 207–213. [CrossRef]
21. Goldsmith, S.R.; Lovell, A.R.; Schroeder, M.A. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy. Drugs Today 2019, 55, 545–562. [CrossRef]
22. Wolska-Washer, A.; Robak, T. Glasdegib in the treatment of acute myeloid leukemia. Future Oncol. 2019, 15, 3219–3232. [CrossRef]
23. Fersing, C.; Mathias, F. Update on glasdegib in acute myeloid leukemia—Broadening horizons of Hedgehog pathway inhibitors. Acta Pharm. 2022, 72, 9–34. [CrossRef]
24. Highlights of Prescribing Information. Daurismo®, Glasdegib Tablets, for Oral Use. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf (accessed on 12 May 2022).
25. Product Monograph Including Patient Medication Information, Daurismo®, Glasdegib Tablets. Available online: https://www.pfizer.ca/sites/default/files/202202/Daurismo_PM_EN_250530_21Jan2022.pdf (accessed on 12 May 2022).
26. Hansen, E.C.; Seadeek, C.S. Crystalline Forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea Maleate. International Patent Application WO 2016170451 A1, 27 October 2016.
27. Moreton, C. Poor Solubility—Where do we stand 25 years after the ‘rule of five’? Am. Pharm. Rev.-Rev. Am. Pharm. Bus. Technol. 2021, 24, 16–22.
28. Peklar, B. Dimaleate Form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea Maleate. International Patent Application WO 2016170451 A1, 27 October 2016.
29. Hussain, S.; Pinitglang, S.; Bailey, T.S.; Reid, J.D.; Noble, M.A.; Resmini, M.; Thomas, E.W.; Greaves, R.B.; Verma, C.S.; Brocklehurst, K. Variation in the pH-dependent pre-steady-state and steady-state kinetic characteristics of cysteine-proteinase mechanism: Evidence for electrostatic modulation of catalytic site function by the neighboring carboxylic anion. Biochem. J. 2003, 372, 735–746. [CrossRef] [PubMed]
30. Agilent Technologies Ltd. CrysAlisPro, Version 1.171.36.28; Agilent Technologies: Yarnton, UK, 2013. Available online: https://www.agilent.com/cs/library/usermanuals/Public/CrysAlis_Pro_User_Manual.pdf (accessed on 8 May 2022).
31. Sheldrick, G.M. SHELXT—Integrated space-group and crystal-structure determination. Acta Crystallogr. C2015, A71, 3–8. [CrossRef]
32. Sheldrick, G.M. Crystal structure refinement with SHELXL. Acta Crystallogr. C2015, C71, 3–8. [CrossRef]
33. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2: A complete structure solution, refinement and analysis program. J. Appl. Crystallogr. 2009, 42, 339–341. [CrossRef]
34. Spek, A.L. Single-crystal structure validation with the program PLATON. J. Appl. Crystallogr. 2003, 36, 7–13. [CrossRef]
35. Lee, M.; Goldberg, W. Nuclear magnetic resonance line narrowing by a rotating RF field. Phys. Rev. 1965, 140, 1261–1271. [CrossRef]
36. Ladizhansky, V.; Vega, S. Polarization transfer dynamics in Lee–Goldburg cross polarization under magnetic resonance experiments on rotating solids. J. Chem. Phys. 2000, 112, 7158–7168. [CrossRef]
37. Van Rossum, B.-J.; de Groot, C.P.; Ladizhansky, V.; Vega, S.; de Groot, H.J.M. A method for measuring heteronuclear (1H–13C) distances in high speed MAS NMR. J. Am. Chem. Soc. 2000, 122, 3465–3472. [CrossRef]
38. Bernstein, J.; Davis, R.E.; Shimoni, L.; Chang, N.L. Patterns in hydrogen bonding: Functionality and graph set analysis in crystals. Angew. Chem. Int. Ed. 1995, 34, 1555–1573. [CrossRef]
39. Cruz-Cabeza, A.J. Acid–base crystalline complexes and the pKa rule. CrystEngComm 2012, 14, 6362–6365. [CrossRef]
40. Childs, S.L.; Stahl, G.P.; Park, A. The salt-cocrystal continuum: The influence of crystal structure on ionization state. Mol. Pharm. 2007, 4, 323–338. [CrossRef]
41. Lengauer, H.; Makuc, D.; Šterk, D.; Perdih, F.; Pichler, A.; Trdan Lušin, T.; Plavec, J.; Časar, Z. Co-crystals, salts or mixtures of both? The case of tenofovir alafenamide fumarates. Pharmaceuticals 2020, 12, 342. [CrossRef]
42. Wang, J.-W.; Liu, L.; Yu, K.-X.; Bai, H.-Z.; Zhou, J.; Zhang, W.-H.; Hu, X.; Tang, G. On the single-crystal structure of tenofovir alafenamide mono-fumarate: A metastable phase featuring a mixture of co-crystal and salt. Int. J. Mol. Sci. 2020, 21, 9213. [CrossRef]
43. ChemAxon Marvin Suite 17.28.0. ChemAxon Home Page. Available online: http://www.chemaxon.com (accessed on 19 June 2022).
44. Clark, J.H.; Jones, C.W. Solvent-dependent proton transfer in a strongly hydrogen bonded fluoride complex. *J. Chem. Soc. Chem. Commun.* 1990, 24, 1786–1787. [CrossRef]
45. Black, S.N.; Collier, E.A.; Davey, R.J.; Roberts, R.J. Structure, solubility, screening, and synthesis of molecular salts. *J. Pharm. Sci.* 2007, 96, 1053–1068. [CrossRef]
46. Paulekuhn, G.S.; Dressman, J.B.; Saal, C. Trends in active pharmaceutical ingredient salt selection based on analysis of the orange book database. *J. Med. Chem.* 2007, 50, 6665–6672. [CrossRef]
47. Ule, M.; Časar, Z. Analysis of the selection of active pharmaceutical ingredients’ salts in medicinal products registered in the USA between 2007 and 2016. *Farm. Vestn.* 2018, 69, 175–187.
48. Bharate, S.S. Carboxylic acid counterions in FDA-approved pharmaceutical salts. *Pharm. Res.* 2021, 38, 1307–1326. [CrossRef]
49. Australian Public Assessment Report for Afatinib (as Dimaleate). Available online: https://www.tga.gov.au/sites/default/files/auspar-afatinib-dimaleate-140414.pdf (accessed on 31 July 2022).
50. Australian Product Information NERLYNX®(Neratinib) Tablets. Available online: https://www.tga.gov.au/sites/default/files/auspar-neratinib-as-maleate-020512-pi.pdf (accessed on 31 July 2022).
51. Highlights of Prescribing Information. SUTENT®(Sunitinib Malate) Capsules, Oral. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf (accessed on 31 July 2022).
52. Loftsson, T.; Thorisdóttir, S.; Fridriksdóttir, H.; Stefánsson, E. Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits. *Acta Ophthalmol.* 2010, 88, 337–341. [CrossRef] [PubMed]